Aerie Pharma (AERI) Tops Q4 EPS by 8c

Aerie Pharma (NASDAQ: AERI) reported Q4 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72).

Aerie Highlights

• With the Company’s successful Rocket 2 topline safety and efficacy readout in February and other preparatory activities underway, Aerie is well positioned to file the NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02% in the third quarter of 2016.
• The first Phase 3 clinical trial for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, Mercury 1, is proceeding forward and its 90-day topline interim efficacy readout is on track for the third quarter of 2016. Mercury 2, the second Phase 3 clinical trial for RoclatanTM, is expected to commence later this month.
• Rocket 4, the Phase 3 clinical trial for RhopressaTM designed to provide adequate safety data for approval by the European regulatory authorities, remains on schedule for topline 90-day efficacy readout in the fourth quarter of 2016.
• As of December 31, 2015, Aerie had $150.4 million in cash, cash equivalents and investments on the balance sheet. In 2015, net cash burn, excluding financing activities, totaled $59.0 million, slightly better than the guidance previously provided by the Company for 2015.

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Movano (MOVE) Misses Q2 EPS by 195c